J Korean Diabetes > Volume 19(1); 2018 > Article
The Journal of Korean Diabetes 2018;19(1):15-22.
DOI: https://doi.org/10.4093/jkd.2018.19.1.15    Published online April 13, 2018.
제2형 당뇨병 환자의 약제치료 개정안 2017: 경구혈당강하제 단일요법
Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association.
Sang Youl Rhee
On Behalf of the Committee of Clinical Practice Guideline of the Korean Diabetes Association, Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. rheesy@khu.ac.kr
When starting initial medication in people with type 2 diabetes mellitus (T2DM), the appropriate drug should be selected considering characteristics of the patient, efficacy, side effects, and cost. It is generally recommended to use metformin as the first-line treatment oral hypoglycemic agent in T2DM patients. Metformin is recommended as the first treatment because of its excellent glucose lowering effect, relatively mild side effects, long-term safety, low risk of hypoglycemia, and small weight gain. If it is difficult to use metformin as a first-line treatment, appropriate drugs can be selected based on the clinical situation.
Key Words: Diabetes mellitus, type 2, Hypoglycemic agents, Metformin, Practice guideline

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer